| Title | Two serological approaches for detection of antibodies to SARS-CoV-2 in different scenarios: a screening tool and a point-of-care test. | ||
| Author | Hoste, Alexis C R; Venteo, Angel; Fresco-Taboada, Alba; Tapia, Istar; Monedero, Alejandro; Lopez, Lissette; Jebbink, Maarten F; Perez-Ramirez, Elisa; Jimenez-Clavero, Miguel Angel; Almonacid, Mercedes; Munoz, Patricia; Guinea, Jesus; Vela, Carmen; van der Hoek, Lia; Rueda, Paloma; Sastre, Patricia | ||
| Journal | Diagn Microbiol Infect Dis | Publication Year/Month | 2020-Dec |
| PMID | 32890908 | PMCID | PMC7417941 |
| Affiliation + expend | 1.Eurofins-Inmunologia y Genetica Aplicada (Eurofins-INGENASA), Madrid, Spain; School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom. | ||
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected more than 8 million people worldwide, becoming a pandemic. Detecting antibodies against SARS-CoV-2 is of utmost importance and a good indicator of exposure and circulation of the virus within the general population. Two serological tools based on a double recognition assay [enzyme-linked immunosorbent assay (DR-ELISA) and lateral flow assay (DR-LFA)] to detect total antibodies to SARS-CoV-2 have been developed based on the recombinant nucleocapsid protein. A total of 1065 serum samples, including positive for COVID-19 and negative samples from healthy donors or infected with other respiratory pathogens, were analyzed. The results showed values of sensitivity between 91.2% and 100%, and specificity of 100% and 98.2% for DR-LFA and DR-ELISA, respectively. No cross-reactivity against seasonal coronavirus (HCoV-NL63, HCoV-229E, HCoV-HKU1, HCoV-OC43) was found. These results demonstrate the importance of serology as a complementary tool to polymerase chain reaction for follow-up of recovered patients and identification of asymptomatic individuals.